Sort   by:  
 Page size 
Resistance to endocrine treatments and CDK4/6 inhibitors is considered a near-inevitability in most patients with estrogen receptor positive breast cancers (ER + BC). By genomic and metabolomics analyses of patients' tumours, metastasis-derived patient-derived xenografts (PDX) and isogenic cell line...
2023-06-27 | MTBLS3342 | MetaboLights
Acquired resistance to endocrine therapy occurs with high frequency in patients with luminal breast cancer (LBC). We report here the establishment of four patient-derived xenograft models of LBC with acquired resistance in vivo to tamoxifen and estrogen deprivation. CEL files represent expresison da...
ORGANISM(S): Homo sapiens 
Data Access Committee EGAC00001001548
Data Access Committee EGAC00001002771
Data Access Committee EGAC00001002772
Data Access Committee EGAC00001003035
Data Access Committee EGAC00001003238
Breast cancer PDTX sequencing data from Bruna et al, Cell 2016 - Exome Sequencing - Shallow Whole Genome Sequencing - RRBS Methylation Sequencing
RNA-SEQ for the Caldas Lab breast cancer PDTX collection. This includes both single and paired end runs
Sort   by:  
 Page size